Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is among the world’s largest Pharmaceuticals sector businesses in the world. Barr Pharmaceuticals, Inc.’s employees generate $222.7M in profits on $2.105B of revenue. Global output in the Pharmaceuticals business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Barr Pharmaceuticals, Inc. is determined to remain a market leader. Sectoral leadership in the Pharmaceuticals segment takes dedication and consistency, but management seeks out-sized growth.

Barr Pharmaceuticals, Inc.’s ticker symbol BRL has recently been trading near $50.76 a share. The Barr Pharmaceuticals, Inc. corporate headquarters in Pomona, NY predicts Pharmaceuticals profits will satisfy shareholders in search of risk-appropriate returns.

The significance of market volume is sometimes ignored, but with a total market capitalization of $5.571B ensures sufficient liquidity. With a beta of 0.35, the company is less volatile than the market as a whole. When the average equity moves lower, Barr Pharmaceuticals, Inc. moves less aggressively.